James A. Datin, Executive Vice President and Managing Director of Life Sciences Group at Safeguard Scientifics, discusses his thoughts on the opportunities in life sciences…
Posted by
On the eve of the International Conference on Alzheimer’s Disease (ICAD), Bloomberg Businessweek’s Elizabeth Lopatto and Kanoko Matsuyama reported that Avid Radiopharmaceuticals, Inc., a Safeguard…
Posted by
While there are a wealth of opportunities to deploy capital in a variety of life sciences companies, the evolution and potential long-term impact of regenerative…
Posted by
Avid Radiopharmaceuticals was featured on the front page of The New York Times today. The article, “Promise Seen for Detection of Alzheimer’s,” by Gina Kolata (@ginakolata), highlights…
Posted by
On the heels of the BIO International Convention, I came across this piece by FierceBiotech’s Maureen Martino highlighting a panel of biotech VCs who made…
Posted by
Our partner company, Avid Radiopharmaceuticals, announced positive interim results from the Phase III clinical trial of its amyloid imaging agent Florbetapir F18 for early diagnosis…
Posted by
I frequently attribute Safeguard Scientifics’ success to our disciplined strategy built on five strategic themes, which we refer to as M2C3. We leverage these themes…
Posted by
Safeguard Scientifics’ strategy is to deploy capital in growth-stage companies in attractive sectors of the life sciences and technology industries. Within life sciences, we target…
Posted by
Molecular Biometrics, Inc., one of Safeguard Scientifics’ Life Sciences partner companies, raised another $12.5 million of capital. The new capital will support three big goals.…
Posted by
